In addition, numerous ADC drugs targeting HER2‐positive breast cancer are currently under clinical investigation.[43] However, regarding TNBC, the approved ADC drug TROP2‐ADC benefits only a very small number of patients owing to its severe hematological toxicity. The gene discussed is ERBB2; the disease is breast carcinoma.